Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Global transcriptomics analysis for TDO2 alteration in human triple-negative breast cancer cell lines

ABSTRACT: To elucidate the downstream transcriptomics changes in reponse to TDO2 alteration including shRNA knockdown, overexpression and TDO2/IDO duak inhibitor treatments in human triple-negative breast cancer cell lines.

ORGANISM(S): Homo sapiens

PROVIDER: GSE253237 | GEO | 2025/01/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Global transcriptomics analysis for TDO2 alteration in human triple-negative breast cancer cell lines

Project description:Global transcriptomics analysis for TDO2 alteration in human triple-negative breast cancer cell lines

| PRJNA1064872 | ENA

Triple-negative breast cancer cell line MDA-MB-231 +/- CD43 knockdown

Project description:The triple-negative breast cancer cell line MDA-MB-231 with high CD43 expression was stably transfected with a vector expressing a non-functional shRNA or 4 of these same vectors each expressing a different shRNA targeting human CD43 mRNA. The transcriptomes of these two daughter lines were then compared by differential microarray analysis.

2021-05-04 | GSE173757 | GEO

Effect of TDO2/IDO dual inhibitor AT0174 on human MDA-MB-453 breast cancer cells

Project description:To investigate global transcriptomics of human MDA-MB-453 breast cancer cells in response to the TDO2/IDO dual inhibitor AT0174 treatment in compared with the vehicle control

2025-01-02 | GSE253238 | GEO

Spatial transcriptomics of triple negative breast cancer

Project description:Spatial transcriptomics of triple negative breast cancer

| PRJNA866496 | ENA

Spatial transcriptomics of triple negative breast cancer

Project description:Triple negative breast cancer (TNBC) is an aggressive and clinically challenging subtype of breast cancer. TNBC disporportionately affects African-American (AA) women, but the biological basis of this disparity is not understood. To gain a better understanding of TNBC, particularly in AA patients, we applied spatial transcriptomics to thoroughly characterize gene expression and tissue architecture in TNBC. Our cohort consisted of 22 patients, 15 of whom were AA, and 7 who were Caucasian. We obtained 2 sections from each patient's tumor (except for patient 19) for a total of 43 samples.

2022-11-02 | GSE210616 | GEO

Effect of depletion of YAP1 on gene expression in triple negative breast cancer

Project description:To investigate the cooperative function HJURP/YAP1/NDRG1 in the regulation of progression in triple negative breast cancer, we established MDA-MB-231 cell lines in which each target gene has been knocked down by shRNA. We then performed gene expression profiling analysis using data obtained from RNA-seq of 2 different cells.

2022-10-24 | GSE201877 | GEO

Triple therapy reduced metastasis in triple-negative breast cancer.

Project description:Triple therapy reduced metastasis in triple-negative breast cancer.

| PRJNA832953 | ENA

Triple Negative Breast Cancer RNA Sequencing

Project description:We propose to definitively characterise the somatic genetics of triple negative breast cancer through generation of comprehensive catalogues of somatic mutations in breast cancer cases by high coverage genome sequencing coupled with integrated transcriptomic and methylation analyses.

2015-04-16 | E-ERAD-113 | biostudies-arrayexpress

Triple Negative Breast tumors: SPARC Positive Tumors vs SPARC Negative Tumors

Project description:The aim of this study was evaluate the transcriptome changes in the comparison between triple negative tumors with increased SPARC expression and triple negative tumors with decreased SPARC expression according to Nagai et al., 2011 (Breast Cancer Res Treat (2011) 126:1–14) The results generated could be of particular interest to better define the prognostic impact of SPARC expression in triple negative breast tumors

2018-07-01 | GSE98931 | GEO

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Project description:This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative breast cancer (currently enrolling only patients with triple-negative breast cancer since 6/8/2007). Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving 7-hydroxystaurosporine together with irinotecan hydrochloride may help kill more cancer cells by making tumor cells more sensitive to the drug.

| 2007227 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data